What are lipoflavonoid pockets?
Lipoflavonoid® Caplets are launched as a proprietary nutritional supplement formulated to alleviate the symptoms associated with Meniere's disease. The formula is the creation of DSE Healthcare Solutions, which has distributed the product under the name Lipoflavonoid® since 1961 and made its subsidy Numark Laboratories. Lipoflavonoid® Caplets, classified as a dietary supplement, are available without a prescription and can be found in most pharmacies and in some supermarkets in the US in the US is why Lipoflavonoid® can be sold as a dietary supplement because it is due to the product formula is emptiness with any synthetic drugs or other regulated drugs. In fact, the product contains only natural ingredients. The active ingredient is Eriodictyol glycoside, which is a bioflavonoid derived from citrus fruits, especially lemon. Other ingredients that provided nutritional support include vitamin C, inositol and pantothenate. However, the formula is composed of complex vitamins B, namely riboflavin, kyanokPayramine, thiamine and niacinamide.
One of the primary characteristics of Meniere's disease is the ringing sound in one or both ears, which is a symptom otherwise known as tinnitus. This happens when stereocilia, slight hair cells of inner ear too much vibrate in response to certain changes in the environment, such as the accumulation of fluid. Tinnitus may also occur for various reasons, but in conjunction with Meniere's disease is usually accompanied by dizziness and loss of the ability to hear low -frequency sounds. Although US food and medicines have not approved lipoflavonoid® pockets as a treatment of Meniere's disease or tinnitus, there are studies that promote the effectiveness of the components found in the product to reduce these symptoms.
Most of these HAVE studies focused on the effects of lemon bioflavonoid or eeriodictyol glycosidase. This agent seems to inhibit histidine decarboxylase, compound that pIt sails to the production of histamine in endothelial cells. One of the first studies included 197 entities with hearing loss initiated by various causes, including Meniere's disease. After supplementing Eriodictyol glycosidase, 36.9% of the vertigo relief therapeutic group reported, but no hearing improvement. However, 41% of the group recorded improvements in both areas.
A larger study involving more than 1200 entities has evaluated the effects of eeriodictyol glycosidase therapy in combination with daily multivitamin, resulting in a 40% therapeutic group that showed a significant improvement in hearing. The following studies have found that the complex of vitamin B12 supplemented by eReriodictyol glycosidase supplementation brought similar results. Another fact that provides support in favor of the completion of the Wtyto compound is that tinnitus was independently associated with the lack of vitamin B-12.